| Fiscal Year End | Company Status | Exempt Flag |
| December 31 | Delist | N |
|
|
|
|
|
| Incorporation Locations |
| Inc. Date | Expiry Date | Country | Region | Description |
| 16/Jan/2004 | 27/Nov/2014 | Canada | Ontario | |
|
|
| Exchange Filing Office |
| Location |
| (not available) |
|
|  |
| Business Type(s) |
| Primary/Secondary | Business Type | Details |
| Primary
| *Research and Development
| May 9, 2013 - Cynapsus is a specialty pharmaceutical company developing the only non-injectable (i.e. sublingual) delivery of the only approved drug (apomorphine) to be used as a rescue therapy for "off" motor symptoms of Parkinson's disease. Over one million people in the U.S. and an estimated 5 million people globally suffer from Parkinson's disease. Parkinson's disease is a chronic and progressive neurodegenerative disease that impacts motor activity, and its prevalence is increasing with the aging of the population. Based on a recent study and the results of the Company's Global 500 Neurologists Survey, it is estimated that between 25 percent and 50 percent of patients experience "off" episodes in which they have impaired movement or speaking capabilities. Current medications only control the disease's symptoms, and most drugs become less effective over time as the disease progresses.
|
|
| *Capital Pool Company
| (not available)
|
|
|
| Securities |
| Symbol | Security Name | Market | Status |
| *CTH | *Cynapsus Therapeutics Inc. | TSX Venture | DELIST |
| *CTH | *Cynapsus Therapeutics Inc. old | TSX Venture | DELIST |
| *CTH | *Cannasat Therapeutics Inc. | TSX Venture | DELIST |
| *LON.P | *Lonsdale Public Ventures Inc. | TSX Venture | DELIST |
|
|
| Name History | From | To |
| *Cynapsus Therapeutics Inc. | 27/Apr/2010 | 27/Nov/2014 |
| *Cannasat Therapeutics Inc. | 23/Mar/2006 | 26/Apr/2010 |
| *Lonsdale Public Ventures Inc. | 3/Jun/2005 | 22/Mar/2006 |
|
|
| Company Facts Reconciliation |
| Subject | Date Returned |
| Fall 2014 CFR | Not Received |
|
|
|
|
|
